Aporphine enantiomers. Interactions with D-1 and D-2 dopamine receptors

The R(-) and the S(+) enantiomers of apomorphine (APO) and N-n-propyl norapomorphine (NPA) interact with both the D-1 and the D-2 dopamine receptors. R(-)-APO, as well as R(-)- and S(+)-NPA, stimulates the D-1 dopamine receptor in carp retina; S(+)-APO blocks this dopamine receptor. Similarly, R(-)-APO, as well as R(-)- and S(+)-NPA, stimulates the D-2 dopamine receptor in the intermediate lobe of the rat pituitary gland; S(+)-APO blocks the intermediate lobe D-2 receptor. The interactions between these aporphine enantiomers and the D-1 and the D-2 dopamine receptors exemplify several manifestations of the previously described "n-propyl phenomenon." Because S(+)-APO is distinguished from the other tested aporphines by its ability to antagonize either the D-1 or the D-2 dopamine receptors, it is hypothesized that the presence of an N-methylated tertiary amine in a molecule of appropriate configuration can confer dopamine receptor antagonist activity to the molecule.     

Potentiation of licking in rats by stimulation of both D-1 and D-2 dopamine receptors

Apomorphine-induced licking in rats was assessed by recording the total number of licks by direct observation. Apomorphine induced licking dose dependently. The maximum response was obtained by 0.5 mg/kg of the drug and 30 min after drug administration. Pre-treatment with dopamine antagonists, sulpiride and SCH 23390 decreased the apomorphine effect. Pre-treatment of animals with reserpine+α-methyl-p-tyrosine (AMPT) increased apomorphine-induced licking. In normal rats the D-2 agonist quinpirole and the D-1 agonist SKF 38393 also induced significant licking. The effect of quinpirole or SKF 38393 was decreased by reserpine+AMPT pre-treatment. Combined treatment with SKF 38393 and quinpirole induced more intense licking in both reserpinized and non-reserpinized animals. It is therefore concluded that the apomorphine-induced licking is mediated through both D-1 and D-2 receptors, and that pre-treatment with reserpine hypersensitizes these receptors to the drug effect. However, for either SKF 38393- or quinpirole-induced licking, the presence of endogenous dopamine seems essential.     

Inactivation of dopamine D-1 or D-2 receptors differentially inhibits stereotypies induced by dopamine agonists in rats

Ex vivo D-1 or D-2 receptor binding in the striatum was reduced by 65-78% after treatment with EEDQ (N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline) in combination with either the D-2 antagonist, raclopride, or the D-1 antagonist, SCH 23390, respectively. EEDQ induced a 65% reduction in D-1 receptor binding and a 51% decrease in cAMP production in striatal homogenates. Selective D-2 receptor inactivation inhibited the stereotyped behaviour induced by the mixed D-1/D-2 agonist, apomorphine, or by the D-2 agonist, quinpirole, when given alone and in combination with the D-1 agonist, SK&F 38393. Selective inactivation of D-1 receptors did not inhibit the behavioural effects of quinpirole when given alone and in combination with the D-1 agonists, SK&F 81297, SK&F 38393 or SK&F 75670. Likewise, the effect of apomorphine was unchanged. These results indicate that a normal density of D-2 receptors is critical for the expression of the stereotyped behaviour induced by DA agonists. In contrast, there is a large surplus of D-1 receptors to enable the response to a D-2 agonist. This is particularly illustrated by the persistent behavioural effects of the partial D-1 agonist, SK&F 75670, in rats with up to a 78% decrease in D-1 receptor binding.     

Role of dopamine D-1 and D-2 receptors in the ventral striatum in the turning behaviour of rats

Systemically administered methamphetamine and apomorphine evoked characteristic turning when rats were pretreated with injections of D-1 and D-2 antagonists in the ventral but not in the dorsal striatum. The frequency of turning was greater for rats pretreated with D-2 antagonists (l-sulpiride and YM-09151-2) than for rats pretreated with a D-1 antagonist (SCH 23390). The responses were apparently additive when rats were pretreated with mixed D-1/D-2 antagonists, (cis(Z)-flupentixol and SCH 23390 + l-sulpiride). These results suggest that dopamine D-1 and D-2 receptors in the ventral striatum mediate turning behaviour through separate but cooperative mechanisms.     

Selective blockade of dopamine D-1 receptors by SCH 23390 discloses striatal dopamine D-2 receptors mediating the inhibition of adenylate cyclase in rats

l-Glutamate but not methyl-D-aspartate (NMDA) or quisqualate (Quis) (10^?6 M) in vitro with or without preincubation increased significantly the K_D value of the [³H]N-propylnorapomorphine ([³H]NPA) binding sites by 21 and 36% respectively in striatal membranes of rat without influencing the striatal [³H]spiperone binding sites. The number of striatal [³H]NPA binding sites was not changed by l-glutamate (10^?6 and 10^?5 M) in vitro. There may thus exist interactions between striatal glutamate receptors — not related to excitatory amino-acid receptors of the NMDA or the QUIS type - and high affinity striatal DA receptors.     

D-1/D-2 behavioural interactions in the rat involving striatal dopamine D-1 receptors

Simultaneous systemic administration of SKF 38393 (1-15 mg/kg i.p.) and LY 171555 (0.625-20 mg/kg s.c.) showed clear evidence of dopamine D-1/D-2 behavioural interactions compared to either treatment given alone. Similar interactions were observed between an intermediate systemic dose of LY 171555 (5 mg/kg) and SKF 38393 (1-10 micrograms) microinjected bilaterally into the caudate-putamen, but not into the substantia nigra pars reticulata, suggesting that striatal dopamine D-1 receptors are the ones responsible for mediating the altered behavioural responses to D-2 agonists in the intact rat.     

Blockade of both D-1 and D-2 dopamine receptors may induce catalepsy in mice.

1. The catalepsy induced by dopamine antagonists has been tested and the possible dopamine subtypes involved in catalepsy was determined. 2. Dopamine antagonist fluphenazine, D-1 antagonist SCH 23390 or D-2 antagonist sulpiride induced catalepsy. The effect of fluphenazine and sulpiride was dose-dependent. Combination of SCH 23390 with sulpiride did not induce catalepsy potentiation. 3. D-1 agonist SKF 38393 or D-2 agonist quinpirole decreased the catalepsy induced by fluphenazine, SCH 23390 or sulpiride. 4. Combination of SKF 38393 with quinpirole did not cause potentiated inhibitory effect on catalepsy induced by dopamine antagonists. 5. The data may indicate that although D-2 receptor blockade is involved in catalepsy, the D-1 receptor may plan a role.     

On the relative importance of D-1 vs. D-2 dopaminergic receptors in the control of audiogenic seizures in ethanol withdrawn rats

Bromocriptine, a mixed D-1/D-2 dopaminergic receptor agonist and SKF 38393, a D-1 specific agonist were found to alleviate the incidence and intensity of audiogenic convulsions in ethanol withdrawn rats. (+) and (-)3-PPP, putative D-2 autoreceptor agonists, were without effect in the test. SCH 23390, a D-1 specific antagonist did not influence seizure intensity in ethanol withdrawn or ethanol naive animals. It is suggested that D-1 receptors may play a role in convulsive response during ethanol withdrawal.     

Brain distribution and fate of tris(2-chloroethyl) phosphate in Fischer 344 rats.

Tris(2-chloroethyl) phosphate (TRCP) is a flame retardant that has a wide variety of industrial applications. In subchronic studies, oral administration of TRCP to rats and mice has been reported to produce dose-, sex-, and species-dependent lesions in the hippocampal brain region. The present investigation has examined the metabolism, elimination, and regional brain distribution of [14C]TRCP in male and female rats. [14C]TRCP was administered by gavage (0, 175, 350, or 700 mg/kg) and urine, feces, exhaled volatiles, CO2, and selected tissues were collected. Regional brain distribution of 14C was determined 2 hr following single doses of TRCP to male and female rats, and 24 hr after a single dose and the last of 14 daily doses of TRCP to female rats. Results of these studies indicate that TRCP is readily absorbed from the gastrointestinal tract, distributed to all brain regions, and that metabolism and excretion are nearly complete in 72 hr. Most of the TRCP-derived radioactivity was excreted in urine (up to 85%), with feces, volatiles, and CO2 combined accounting for less than 10% of the dose. Predominant signs of toxicity associated with TRCP administration (350 and 700 mg/kg) were seizures within 2 hr of treatment, when most of the TRCP-derived radioactivity present in brain tissue was in the form of the parent compound. Traces of inextractable 14C were detected at later times, but this material was not concentrated in brain relative to other tissues.(ABSTRACT TRUNCATED AT 250 WORDS)     

Stimulation of D-1 dopamine receptors facilitates D-2 dopamine receptor recovery after irreversible receptor blockade

The hypothesis that stimulation of the D-1 dopamine receptor subtype affects the recovery of the D-2 subtype after alkylation by EEDQ was investigated. Animals were pretreated with either SCH23390, to protect D-1 receptors, or saline, before administration of EEDQ. After EEDQ one group of saline pretreated animals received 12 hourly injections of the D-1 agonist SKF38393. Animals were sacrificed at 6, 24 and 48 hours after EEDQ and Kd and Bmax of striatal D-1 and D-2 receptors measured. The concentration of D-2 receptors in the groups in which D-1 receptors had been protected by SCH23390 or stimulated by SKF38393 were significantly greater than that of the EEDQ alone group.     

SCH 23390 blocks D-1 and D-2 dopamine receptors in rat neostriatum in vitro

Summary The agonistic and antagonistic effects of the new compound SCH 23390 were tested in functional model systems for the D-1 dopamine receptor and for the D-2 dopamine receptor in vitro. In superfused rat neostriatal slices the increase in the efflux of cyclic AMP was used as a parameter for D-1 receptor stimulation. D-2 receptor stimulation was measured as the decrease in the K⁺-evoked release of [³H]-acetylcholine. SCH 23390 had no agonistic activity in these two models. SCH 23390 was a potent antagonist of the stimulating effect of dopamine in the D-1 receptor model (apparent pA₂=7.28). SCH 23390 also antagonized the effect of the D-2 receptor agonist LY 141865 in the D-2 receptor model (apparent pA₂=6.34). This D-2 receptor antagonism proved to be of a competitive nature.     

Effects of adrenalectomy on responses mediated by dopamine D-1 and D-2 receptors

The effects of surgical adrenalectomy were investigated on behavioural responses produced by the selective D-1 agonist, SK&F 38393, alone, and in combination with the D-2 agonist, quinpirole (LY171555). Further, stereotyped responses to apomorphine and LY171555 were assessed following treatment with either the D-1 or the D-2 antagonists, SCH 23390 and raclopride, respectively. There was no difference between sham-adrenalectomized (sham) and adrenalectomized (ADX) groups in responses to SK&F 38393. Although concomitant stimulation of both receptor subtypes increased the incidence of stereotyped sniffing behaviour, there was no difference in the magnitude of this effect between the sham and ADX groups. Raclopride reduced LY171555-induced sniffing and hypothermia less in ADX rats than in sham controls, which was consistent with the hypothesis that adrenocortical hormones affect D-2 receptor responsiveness. SCH 23390 had a greater inhibitory effect on LY171555 responses, but a smaller effect on apomorphine responses in the ADX group compared with their sham controls. It is concluded that the amplified D-2-stimulated response observed in ADX rats may be more dependent on tonic D-1 receptor activation than the control D-2 response of shams.     

Sulpiride isomers exhibit reversed stereospecificity for D-1 and D-2 dopamine receptors in the CNS

We have investigated the stereospecificity of the interaction of (?) and (+)sulpiride with [³H]cis-flupentixol and [³H]spiperone binding to D-1 and D-2 dopamine receptors respectively in rat strialum. Both isomers of sulpiride compete more potently at D-2 vs. D-1 dopamine receptors. (?)Sulpiride is 50-fold more potent than (+)sulpiride in blocking D-2 receptors, while (+)sulpiride is 3-fold more potent than (?)sulpiride at D-1 receptors. This reversed stereospecificity of sulpiride interactions with CNS D-1 and D-2 dopamine receptors is similar to the stereospecificity of sulpiride interactions at DA₁ and DA₂ dopamine receptors in peripheral vascular beds.Biochemical and radioligand binding studies indicate the presence of D-1 and D-2 dopamine receptor subtypes in the central nervous system (CNS) (Creese, Sibley, Hamblin and Leff, 1983). Pharmacological studies suggest that a similar subclassiflcation may be made for dopamine receptors found in peripheral vascular beds based on their postsynaptic (DA₁) or presynaptic (DA₂) localization (for review see Goldberg and Kohli, 1982). Some pharmacological data suggest that similarities may exist between D-1 vs. DA₁ and D-2 vs. DA dopamine receptor subtypes (Goldberg and Kohli, 1982; Creese, 1983; Shepperson, Duval, Massingham and Langer, 1982; Schmidt and Imbs, 1980). Interestingly, all investigations indicate that DA₁ and DA₂ receptors show an opposite stereoselectivity for the (?)(S) and (+)(R) stereoisomers of sulpiride whereby DA₂ receptors are more potently blocked by (?)sulpiride vs. (+)sulpiride and DA₁ receptors are slightly more sensitive to (+)sulpiride vs. (?)sulpiride. The present study reports a similar stereoselectivity for CNS D-2 and D-1 dopamine receptors, respectively, measured by radioligand binding techniques.     

Subchronic inhalation study of 1-hexene in Fischer 344 rats.

The objective of this study was to evaluate the toxicity of 1-hexene following repeated inhalation exposures in male and female Fischer 344 rats. Groups of 40 male and 40 female rats were exposed for 6 hours per day, 5 days per week, over a 13-week period. Treatment groups consisted of air-exposed control (0 ppm) and three test groups of 300, 1000, and 3000 ppm 1-hexene. During the treatment period, the rats were observed daily for clinical signs of toxicity; body weights and neuromuscular coordination [females only] were measured at 7-day intervals. After 7 weeks of exposure and at the end of the treatment period, the rats were subject to macroscopic and microscopic pathology, clinical chemistry, hematology, urinalysis, and sperm counts. No mortalities were observed during the course of the study. No clinical signs of toxicity attributable to 1-hexene exposure were observed. Female rats exposed to 3000 ppm had significantly lower body weights compared to control rats from exposure day 5 persisting throughout the treatment period. Male rats exposed to 3000 ppm had slightly but not statistically significant lower body weights in comparison to controls. Male rats exhibited slightly increased absolute and relative testicular weights, and female rats had slightly decreased absolute [but not relative] liver and kidney weights, at 3000 ppm. There were no gross or microscopic morphological findings attributed to treatment. Exposure to 1-hexene did not affect neuromuscular coordination in females as determined using the Rotarod, nor sperm counts in male rats. Several statistically significant effects in hematology, clinical chemistry, and urinalysis evaluations were observed, but were either of small magnitude or did not correlate with histopathological findings, and thus did not appear to be of biological significance. In summary, the no-adverse-effect-level for this study was determined to be 1000 ppm, based on decreased weight gain in female rats, and on slight organ weight changes in both sexes at 3000 ppm.     

3H]dopamine binds to D-1 and D-2 receptors in rat striatum

Although saturation studies suggest that [3H]dopamine binds to a homogeneous class of stereospecific sites in rat striatal membranes, pharmacologic analysis reveals two distinct sites, one with high and another with low antagonist affinities. The affinity of antagonists for the first site is correlated with their affinity for [3H]butyrophenone binding sites; affinity for the second site is correlated with inhibitory potency against the dopamine-stimulated adenylate cyclase. These results suggest that [3H]dopamine binds to D-1 and D-2 receptors.     

Synergistic effects between D-1 and D-2 dopamine antagonists on catalepsy in rats

The effect of selective D-1 and D-2 dopamine agonists on catalepsy induced by various dopamine antagonists was studied. A potent and selective D-2 antagonist, YM-09151 (YM-09151-2) at a dose of 1.2 mg/kg, SC and a selective D-1 antagonist, SCH 23390 at 1.0 mg/kg, SC induced catalepsy in rats. Mixed D-1/D-2 antagonists, haloperidol (HPD) and cis-flupentixol (FLU) also induced catalepsy at doses of 2.0 and 0.8 mg/kg, SC, respectively. A mixed D-1/D-2 agonist, apomorphine (1.0 mg/kg, SC), a selective D-2 agonist, bromocriptine (10 mg/kg, IP) and a muscarinic antagonist, scopolamine (1.0 mg/kg, SC), prevented or markedly reduced the incidence of catalepsy by the tested antagonists. In contrast, a selective D-1 agonist, SKF 38393 (4.0 mg/kg, SC) did not reduce the cataleptogenic effects of HPD, FLU and SCH 23390, but did reduce the effect of YM-09151. Moreover, co-administration of YM-09151 with SCH 23390 produced a marked increase in the incidence of catalepsy. The incidence seen after the combination of YM-09151 and SCH 23390 at low doses was significantly different from that seen after each drug alone at the doubled dose. Thus, D-1 and D-2 antagonists potentiated each other's effect in producing catalepsy. These results suggest an important role of both D-1 and D-2 receptors in the catalepsy and the existence of synergistic effects of D-1 and D-2 receptor blockade.     

Involvement of septal and striatal dopamine D-2 receptors in yawning behavior in rats

A behavioral study was performed in an attempt to understand the neuronal mechanisms involved in yawning behavior in rats. Subcutaneous injections of low doses of apomorphine (0.05–0.25 mg/kg) or piribedil (0.2–1.0 mg/kg), which preferentially activate presynaptic dopamine autoreceptors at those doses, evoked yawning. Marked yawning responses were also elicited by both 3-PPP (5–20 mg/kg, SC) and TL-99 (1–2 mg/kg, SC). SK & F 38393, a dopamine D-1 receptor agonist, at doses ranging from 0.1 to 8.0 mg/kg (SC) induced neither yawning nor stereotypy. However, bromocriptine (0.5–32.0 mg/kg, SC), a dopamine D-2 receptor agonist, induced yawning for which the dose-response curves showed a bell-shaped form. After a higher dose of 32 mg/kg (SC) bromocriptine, some rats occasionally showed sniffing and sawdust chewing. Yawning responses induced by systemic injection of apomorphine, piribedil, 3-PPP or bromocriptine were wholly suppressed after treatment with sulpiride (10 mg/kg SC), a dopamine D-2 receptor antagonist. Bilateral injections of apomorphine (20 g/side×2), piribedil (100 g/side×2) or 3-PPP (50, 100 g/side×2) into the striatum or septum also elicited marked yawning. The results indicate that low doses of apomorphine, piribedil, 3-PPP, TL-99 or bromocriptine elicit yawning by stimulating dopamine D-2 receptors and striatal and septal dopaminergic systems may be related to the occurrence of yawning behavior.     

Behavioural evidence for the functionality of D-2 but not D-1 dopamine receptors at multiple brain sites in the 6-hydroxydopamine-lesioned rat

Lisuride (D-2 agonist) and SKF 38393 (D-1 agonist) evoked characteristic circling and stereotyped orofacial movements when administered systemically or stereotaxically into the supersensitive caudate nucleus of unilaterally 6-hydroxydopamine-lesioned rats, which were respectively blocked by D-2 and D-1 antagonists. Lisuride induced similar behaviours from the accumbens, frontal cortex, pallidum, ventromedial thalamus, substantia nigra and periaqueductal grey, while SKF 38393 did not. Multiple brain sites may mediate D-2-induced (not D-1) behaviours following treatment with 6-hydroxydopamine.     

Immunotoxicity of 2-methoxyethanol following oral administration in Fischer 344 rats.

The immunotoxicity of the glycol ether 2-methoxyethanol (ME) was evaluated in adult Fischer 344 rats using a variety of in vitro and in vivo immune function assays. In the first phase of this study, male rats were dosed by oral gavage with ME in water, at dosages ranging from 50 to 200 mg/kg/day, for 10 consecutive days. Decreases in thymus weights were observed at dosages of 50-200 mg/kg/day in the absence of decreased body weights. Lymphoproliferative (LP) responses to concanavalin A and phytohemagglutinin were reduced at 50-200 mg/kg/day while pokeweed mitogen and Salmonella typhimurium mitogen responses were reduced at 200 mg/kg/day. No alterations were observed in natural killer cell activity, mixed lymphocyte reaction, or cytotoxic T lymphocyte responses. The frequency of W3/25-positive splenocytes was reduced in rats dosed at 200 mg/kg/day. Interleukin-2 production was reduced in splenocytes from rats exposed to all dosages of ME. The plaque-forming cell (PFC) response to sheep red blood cells was enhanced in rats dosed at 50 mg/kg/day. However, the PFC response to trinitrophenyl-lipopolysaccharide (TNP-LPS) was suppressed at all dosages. Similarly, the PFC response to TNP-LPS was suppressed in adult female rats dosed with ME. A reduction in the expulsion of adult worms was observed in rats dosed at 200 mg/kg/day that were infected with Trichinella spiralis. A number of male reproductive parameters were also evaluated in rats dosed with ME over 10 days. A significant reduction in testicular weight was observed in rats dosed at 200 mg/kg/day. In the second phase of this study, the PFC response to TNP-LPS was employed to assess the role that metabolism of ME to 2-methoxyacetic acid (MAA) plays in the immunotoxicity of this glycol ether. Ten-day oral dosing with MAA resulted in the inhibition of the PFC response to TNP-LPS at dosages of 50-200 mg/kg/day. Concomitant exposure of rats to ME and the alcohol dehydrogenase inhibitor 4-methylpyrazole blocked ME-induced suppression of this PFC response. Attempts to ameliorate ME-induced suppression of the PFC response with serine, which has been shown to reverse ME-induced developmental and reproductive toxicity, were unsuccessful. These results suggest that the immune system may be more sensitive than the reproductive system to the toxic effects of ME. Furthermore, it appears that MAA is the proximate toxicant for ME-induced alterations in the immune system, as has been demonstrated for ME-induced reproductive and developmental toxicity.